CRMD Stock Summary and Trading Ideas (Cormedix | NASDAQ:CRMD)

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.

Cormedix trades on the NASDAQ stock market under the symbol CRMD.

As of February 5, 2026, CRMD stock price declined to $7.61 with 507,981 million shares trading.

CRMD has a beta of 1.32, meaning it tends to be more sensitive to market movements. CRMD has a correlation of 0.06 to the broad based SPY ETF.

CRMD has a market cap of $599.58 million. This is considered a Small Cap stock.

Last quarter Cormedix reported $104 million in Revenue and $.57 earnings per share. This beat revenue expectation by $18 million and met earnings estimates .

In the last 3 years, CRMD traded as high as $17.43 and as low as $2.57.

The top ETF exchange traded funds that CRMD belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.

CRMD has underperformed the market in the last year with a return of -27.4%, while the SPY ETF gained +14.4%. In the last 3 month period, CRMD fell short of the market, returning -33.4%, while SPY returned +1.1%. However, in the most recent 2 weeks CRMD has outperformed the stock market by returning +3.8%, while SPY returned -0.6%.

CRMD support price is $7.48 and resistance is $8.20 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRMD shares will trade within this expected range on the day.